Endocrine and cytostatic treatment of experimental mammary cancer.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D002330:Carmustine / Q000008:administration & dosage / Q000633:toxicity; D002369:Castration; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000633:toxicity; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000633:toxicity; D008770:Methylnitrosourea; D051379:Mice; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage / Q000633:toxicity; D051381:Rats; D013629:Tamoxifen / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage / Q000633:toxicity
D000970:Antineoplastic Agents; D004873:Ergolines; D009607:Nitrosourea Compounds; D013629:Tamoxifen; D015127:9,10-Dimethyl-1,2-benzanthracene; D014750:Vincristine; D008770:Methylnitrosourea; C100271:ergocornine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D005472:Fluorouracil; D002330:Carmustine; D008727:Methotrexate